Injectable Drug Delivery conference 2018

SMi Group16 - 17 May 2018, London, UK.
The SMi Group are thrilled to present the launch of Injectable Drug Delivery Conference 2018. The event is taking place in central London on 16th and 17th May 2018, with two pre-conference workshops occurring on 15th May 2018.

The Global Injectable Drug Delivery Market is expected to reach $789.7 billion USD by 2024, with a compound annual growth rate (CAGR) of 11.5% during the period of 2017 to 2024, according to Research Markets Reports. Therefore, this conference will aim to discuss the key developments in this field and the latest technological advancements.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Jean-René Authelin, Global Head, Pharmaceutical Engineering, Sanofi
  • Joel Richard, Senior Vice President, Peptides Development, Ipsen

Featured speakers:

  • Anand Subramony, Vice President, Novel Product Technologies, MedImmune
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • Maxime Gaillot, Senior Device Engineer, Roche
  • Pierre Goldbach, Senior Principal Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche AG
  • Fie Falck Larsen, Senior Usability Engineer, Injection Devices, Global Research and Development, LEO Pharma
  • Francesco Malavasi, Medical Device Quality Device Risk Manager, Novartis

Featured highlights:

  • Review device designs for a future portfolio
  • Explore risk management options for combination products
  • Hear how companies are tackling compatibility challenges of biologics with high volume injectors
  • Learn how vial-based novel delivery technologies can overcome complex dosing regiments
  • Discover how nanosystems can help address present and future challenges in injectable peptide delivery

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/injectable-drug-delivery

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...